September 7, 1999
Mr. Per-Xxxx Xxxxxxxxx
Xx. Xxxxx Xxxxxx
Q-Med AB
Xxxxxxxxxxxxxx 00
XX-000 00 Xxxxxxx
Xxxxxx
Gentlemen:
This is an amended and restated agreement in principle, pursuant to
which Q-Med AB, a Swedish company with offices in Uppsala, Sweden ("Q-Med"), or
a wholly-owned subsidiary thereof, may acquire a 50% interest in the capital
stock of Ixion Biotechnology, Inc., a Delaware corporation with offices in
Alachua, Florida ("Ixion"), for consideration including the purchase of
newly-issued common stock of Ixion, the execution of a royalty free license to
Q-Med's non-animal stabilized hyaluronic acid ("NASHA") technology in the field
of islet cell encapsulation, and certain other consideration. This amended and
restated Agreement replaces, in its entirety, all prior agreements between Q-Med
and Ixion, including the agreement executed on April 16, 1999.
1. Ixion shall issue to Q-Med an option to acquire shares of
newly-issued common stock of Ixion. Terms of the option shall include the
following:
a) the exercise of the option shall be at the sole discretion
of Q-Med;
b) the number of shares to be acquired shall be (i)
2,700,000 shares, or (ii) a number of shares such that,
following the exercise of the option, Q-Med shall own not
less than 50% (on a fully-diluted basis) of Ixion's common
equity, whichever Q-Med shall elect;
c) the option, if exercised, will be exercised for all, but not
less than all, of the number of shares set forth in section
1(b)(i) or 1(b)(ii) above;
d) the option will expire (i) upon termination of this
Agreement or (ii) July 1, 2000, whichever is earlier; e)
the cash exercise price will be $2.00 per share;
f) on the option exercise date, Q-Med shall pay an amount equal
to 50% of the aggregate cash purchase price for the total
shares to be purchased;
g) on the first anniversary of the option exercise date, Q-Med
shall pay an amount equal to the remainder of the aggregate
cash purchase price for the shares to be purchased;
f) the option shall be subject to Florida law; and
i) the form of option, which shall be drafted by counsel for
Ixion, will contain customary anti-dilution provisions,
customary representations and warranties, and such other
terms as are reasonable and customary.
2. Prior to the option exercise date, Q-Med shall purchase Ixion
common stock as follows:
(a) 150,000 shares for $300,000 on April 16, 1999;
(b) 37,500 shares for $75,000 on August 15, 1999; and
(c) 37,500 shares at $2.00 per share on the 15th of each month
thereafter, through the option exercise date or the
exercistermination date of this Agreement. Upon request by
Ixion, Q-Med shall advance up to one month's purchase.
3. The funds received by Ixion pursuant to section 2 above shall be
expended on operating and interest expenses, including reasonable support for
Ixion's diabetes program, and shall not be used to retire debt or equity or for
any other material transaction not in the ordinary course of business. Ixion
will furnish Q-Med monthly unaudited balance sheet, income statement, and cash
flow statement promptly following the close of each month, and such other
financial or other information as Q-Med shall reasonably request.
4. In connection with this Agreement, Ixion has delivered a
statement (attached hereto as Attachment A) of milestones and specific goals,
together with a supporting budget, for its diabetes division for the 12-month
period commencing with the date of this Agreement. Such milestones and goals are
subject to the review and approval of Q-Med. The work pursuant to Attachment A
shall be subject to the oversight of a Project Committee, the members of which
shall be Xx. Xxxxx Xxxxxx and Xx. Xxxxx X. Xxxx (or such other persons as the
parties shall designate). The Project Committee shall meet at least quarterly,
or on such other schedule as Q-Med shall determine.
5. This Agreement may be terminated as follows :
(a) by Q-Med upon 90 days' prior written notice; or
(b) by either party, if the option is not exercised and the
option period is not extended, on July 1, 2000.
6. The Agreement set forth in this letter shall be a binding
agreement between us, subject to the approval by the boards of directors of the
parties to be granted not later than 30 September 1999.
7. The parties shall promptly negotiate and execute a royalty-free,
exclusive, world-wide license for Ixion to use NASHA-gel, produced by Q-Med, as
an encapsulation material for Ixion islets. Such license shall be drafted by
counsel for Q-Med. In the event that the option is not exercised, nor the option
period extended, the parties agree to renegotiate the terms of such license to
provide for reasonable future royalty payments to Q-Med.
8. Upon the exercise of the option, Ixion and Q-Med will make the
following offer to holders of Ixion's unsecured convertible debentures:
(a) All holders will be given 60 days from the option exercise
date to elect to convert their debentures into Ixion shares
at the price of $2.00 per share;
(b) Q-Med will offer to redeem, at the maturity date, from all
holders electing not to convert at such date, all unsecured
debt at a price equal to par, plus, in the case of variable
rate unsecured debt only, an amount equal to accrued
interest at 10% for the life of the debenture.
9. The parties agree to consult with each other regarding any press
releases or other public disclosures related to this Agreement or the
transactions contemplated hereby. Q-Med understands that the U.S. federal
securities laws will apply to disclosures required to be made by Ixion.
10. Where notice is called for under this Agreement, it shall be
given, by email (confirmed by mail), by fax (confirmed by mail), or by placing
the notice in the mail, addressed to the other party at the addresses set forth
in this Agreement, postage prepaid.
If the forgoing correctly sets forth our agreement,
please sign and return to us the copy of this letter enclosed for the purpose,
at which time this letter shall become a binding agreement between us.
Sincerely yours,
______/S/_______
Xxxxxx X. Xxxxxx
Chairman and Chief Executive Officer
Q-Med AB
By:
Per-Xxxx Xxxxxxxxx
Managing Director
Attachment
